Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
Disease Category: Rheumatoid Arthritis
Location: United States, MD
Phase 3b Golimumab Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients who have Inadequate disease control despite treatment with Etanercept (Enbrel) or Adalimumab (Humira)
Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.
GOLIMUMAB- Research continues on the use of this TNF inhibitor with two trials available -one for biologic naïve patients and a second for biologic nonresponders. The biologic nonresponders are randomized to delivery systems, so all participating patients will have the benefit of a TNF inhibitor. This is a unique opportunity for patients without insurance to receive this class of therapies.
CW ID: 169937
Date Last Changed:
July 23, 2013
The Center for Rheumatology and Bone Research2730 University Blvd West, Suite 306Wheaton, MD 20902Phone: 301 942-6610Fax: 301 942-7833
The Center for Rheumatology and Bone Research
If you would like to learn more about participating in this research study, please email the trial contact using the form below.
We value your privacy and your information will only be used by the research center to contact
you regarding this study.
DISCLAIMER: CenterWatch does not conduct clinical research.
CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies,
contract research organizations, clinical research sites and other interested parties. This information
is designed to help patients find clinical trials of interest and contact the research centers
conducting the trials.
Copyright © 1995-2017 CenterWatch.